These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24294969)

  • 1. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
    Bregman H; Chakka N; Guzman-Perez A; Gunaydin H; Gu Y; Huang X; Berry V; Liu J; Teffera Y; Huang L; Egge B; Mullady EL; Schneider S; Andrews PS; Mishra A; Newcomb J; Serafino R; Strathdee CA; Turci SM; Wilson C; DiMauro EF
    J Med Chem; 2013 Jun; 56(11):4320-42. PubMed ID: 23701517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.
    Shultz MD; Cheung AK; Kirby CA; Firestone B; Fan J; Chen CH; Chen Z; Chin DN; Dipietro L; Fazal A; Feng Y; Fortin PD; Gould T; Lagu B; Lei H; Lenoir F; Majumdar D; Ochala E; Palermo MG; Pham L; Pu M; Smith T; Stams T; Tomlinson RC; Touré BB; Visser M; Wang RM; Waters NJ; Shao W
    J Med Chem; 2013 Aug; 56(16):6495-511. PubMed ID: 23844574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
    Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
    J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
    Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
    J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular insights on TNKS1/TNKS2 and inhibitor-IWR1 interactions.
    Kirubakaran P; Kothandan G; Cho SJ; Muthusamy K
    Mol Biosyst; 2014 Feb; 10(2):281-93. PubMed ID: 24291818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
    Shirai F; Mizutani A; Yashiroda Y; Tsumura T; Kano Y; Muramatsu Y; Chikada T; Yuki H; Niwa H; Sato S; Washizuka K; Koda Y; Mazaki Y; Jang MK; Yoshida H; Nagamori A; Okue M; Watanabe T; Kitamura K; Shitara E; Honma T; Umehara T; Shirouzu M; Fukami T; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2020 Apr; 63(8):4183-4204. PubMed ID: 32202790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
    Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
    J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
    Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
    Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
    Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.
    Samain F; Ekblad T; Mikutis G; Zhong N; Zimmermann M; Nauer A; Bajic D; Decurtins W; Scheuermann J; Brown PJ; Hall J; Gräslund S; Schüler H; Neri D; Franzini RM
    J Med Chem; 2015 Jun; 58(12):5143-9. PubMed ID: 26061013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel binding mode of a potent and selective tankyrase inhibitor.
    Gunaydin H; Gu Y; Huang X
    PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tankyrases as drug targets.
    Lehtiö L; Chi NW; Krauss S
    FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
    Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
    ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
    Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.